Considerations for demonstrating comparability of AAV processes
Cell & Gene Therapy Insights 2022; 8(3), 475–479
DOI: 10.18609/cgti.2022.071
Published: 26 April 2022
Viewpoint
Laura Giersch
“...it is important to try to stockpile material
during different virus productions in order to
ensure that if a comparability study is required
one day, the requisite material will be available.”
